CLINICAL_TRIALS
trial_result
· 2023-05-12
Clinical Trial Update: IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma. [Phase 2]
Summary
Phase 2 trial update examining IBI376 plus rituximab in untreated indolent lymphoma (non-Hodgkin lymphoma).
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Chinese PLA General Hospital | Conditions: Inert Non Hodgkin's Lymphoma | Phase 2 | Status: UNKNOWN